Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Date Added
June 22nd, 2022
PRO Number
Pro00121172
Researcher
Albert Lockhart

List of Studies

Keywords
Cancer
Summary

This study is for patients with invasive cancer I-IV and be scheduled to receive anti-PD-1/-L1 ICI-containing therapy. This study is being done to see if we can understand which patients will develop side effects from immune checkpoint inhibitors, and what kind of side effects they will get and can we predict long-term treatment outcomes after immune checkpoint inhibitor treatment, like which patients will have a cancer that shrinks or disappears.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
(843) 792-9321
hcc-clinical-trials@musc.edu

A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

Date Added
May 23rd, 2022
PRO Number
Pro00121054
Researcher
Albert Lockhart

List of Studies

Keywords
Cancer/Gastrointestinal, Esophagus
Summary

This study is for patients with locoregional esophageal or gastroesophageal junction (GEJ) adenocarcinoma. This study is being done to find out if adding immunotherapy before and after usual approaches are better or worse than the usual approach for your locoregional esophageal or gastroesophageal junction adenocarcinoma.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
(843) 792-9321
hcc-clinical-trials@musc.edu

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Date Added
January 27th, 2022
PRO Number
Pro00117978
Researcher
Albert Lockhart

List of Studies

Keywords
Pancreas
Summary

This study is for people with pancreatic cysts. This study is being done to see
which approach, less frequent monitoring or more frequent monitoring, will lead to better outcomes.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
Broe@tidelandshealth.org

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Date Added
January 11th, 2022
PRO Number
Pro00117676
Researcher
Albert Lockhart

List of Studies

Keywords
Cancer
Summary

This study is for patients who have cancer and are experiencing loss of weight and appetite. The study wants to find out if this taking olanzapine for four weeks will increase your appetite as compared to megestrol acetate. The study is looking to see if that approach is better or worse than the usual approach for your loss of appetite and weight. The usual approach is defined as care most people get for loss of appetite.

Institution
MUSC
Recruitment Contact
Barbara Roe
843-652-1607
Broe@tidelandshealth.org



-- OR --